Ganfort PF

Per mL Bimatoprost 0.3 mg, timolol 5 mg

Reduction of IOP in patients w/ open-angle glaucoma or ocular HTN who are insufficiently responsive to topical β-blockers or prostaglandin analogues.

1 drop in the affected eye(s) once daily in the morning or evening at the same time each day.

Hypersensitivity. Patients w/ reactive airway disease including existing or history of bronchial asthma, severe COPD; sinus bradycardia, sick sinus syndrome, SA nodal block, 2nd-or 3rd-degree AV block uncontrolled w/ pacemaker, overt cardiac failure, cardiogenic shock.

Patients w/ active intraocular inflammation (eg, uveitis); inflammatory ocular conditions, neovascular, inflammatory, angle-closure, congenital or narrow-angle glaucoma; preexisting or history of CV disease (eg, CHD, Prinzmetal's angina 1st degree heart block & cardiac failure); hypotension; severe peripheral circulatory disturbance/disorders (ie, Raynaud's phenomenon); mild or moderate COPD; corneal disease. History of atopy or severe anaphylactic reactions. Aphakic, pseudophakic patients w/ torn posterior lens capsule or w/ known risk factors for macular edema (eg, intraocular surgery, retinal vein occlusions, ocular inflammatory disease & diabetic retinopathy); diabetics (especially those w/ labile diabetes). May mask signs of hyperthyroidism or acute hypoglycemia; induce dryness of eyes. Cardiac disorders. Choroidal detachment. Potential permanent increased brown iris pigmentation, periocular skin & eyelash darkening; periorbital tissue pigmentation; potential for hair growth in skin surface w/ repeated contact w/ soln. May decrease IOP-lowering effect w/ frequent exposure of >1 dose daily. Monitor for IOP changes in patients using other prostaglandin analogs. Concomitant use w/ systemic β-adrenergic blocking agents. May impair compensatory tachycardia & increase risk of hypotension w/ anesth. Remove contact lenses prior to administration & reinsert at least 15 min after instillation. May have negligible influence on ability to drive and use machines. Renal or hepatic impairment. Pregnancy. Not to be used during lactation. Ped patients.

Conjunctival hyperemia, eye pruritus, pain & irritation, dry eye, punctate keratitis, foreign body sensation in eyes, eyelash growth, increased lacrimation, conjunctival irritation, photophobia, eyelid erythema; headache; skin (periocular) hyperpigmentation. Hypoglycemia.

Potential additive effects w/ systemic (eg, oral or IV) β-adrenergic blocking agents; oral Ca channel blockers, anti-arrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics, guanethidine & other antihypertensives. Mydriasis w/ adrenaline. Potentiated systemic β-blockade w/ CYP2D6 inhibitors (eg, quinidine, SSRIs).

Antiglaucoma Preparations

S01ED51 - timolol, combinations ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.

S